浙商证券股份有限公司 关于浙江华海药业股份有限公司 募投项目结项并将节余募集资金永久补充流动资金的 核查意见 浙商证券股份有限公司（以下简称"浙商证券"或"保荐机构"）作为浙江 华海药业股份有限公司（以下简称"华海药业"或"公司"）公开发行可转换公 司债券的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所 股票上市规则》《上市公司募集资金监管规则》《上海证券交易所上市公司自律监 管指引第1号——规范运作》《上海证券交易所上市公司自律监管指引第11号—— 持续督导》等有关规定，对华海药业募投项目结项并将节余募集资金永久补充流 动资金事项进行了审慎核查，发表如下意见： 一、募集资金及募投项目基本情况 （一）募集资金基本情况 经中国证券监督管理委员会证监许可[2020]2261 号文《关于核准浙江华海药 业股份有限公司公开发行可转换公司债券的批复》的核准，华海药业已公开发行 1,842.60 万张可转换公司债券，每张面值 100 元。本次发行募集资金总额为 184,260.00 万元，扣除发行费用 2,089.55 万元（不含税），实际募集资金净额为 182,170.45 万元。 （二）募投项目基本情 ...

浙商证券股份有限公司 一、募集资金基本情况 经中国证券监督管理委员会《关于同意浙江华海药业股份有限公司向特定对 象发行股票注册的批复》（证监许可〔2024〕480号）批准，浙江华海药业股份有 限公司（以下简称"公司"）向特定对象发行人民币普通股（A股）数量为 41,152,263股，发行价格为14.58元/股，募集资金总额为599,999,994.54元，扣除 发行费用17,680,629.03元（不含增值税）后，募集资金净额为582,319,365.51元。 上述募集资金已于2025年3月14日全部到位。天健会计师事务所（特殊普通合伙） （以下简称"天健所"）对上述募集资金到位情况进行了审验，并出具了《验资 报告》（天健验〔2025〕48号）。 募集资金到账后，公司对募集资金进行了专户存储，并与保荐机构、存放募 集资金的银行签署了募集资金专户存储三/四方监管协议。 二、募集资金使用计划及使用情况 （一）募集资金使用计划 关于浙江华海药业股份有限公司 部分募集资金投资项目延期的核查意见 浙商证券股份有限公司（以下简称"浙商证券"或"保荐机构"）作为浙江 华海药业股份有限公司（以下简称"华海药业"或"公司"）向 ...

| 证券代码：600521 | 证券简称：华海药业 | 公告编号：临 2025-085 号 | | --- | --- | --- | | 债券代码：110076 | 债券简称：华海转债 | | 浙江华海药业股份有限公司 关于募投项目结项并将节余募集资金永久补充流动资金的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●本次结项的募投项目名称："浙江华海生物科技有限公司 ADC 产业化技改项 目"。 ●节余募集资金金额及用途：本次节余募集资金金额为 963.07 万元（实际金额 以资金转出当日募集资金专用账户余额为准），公司拟将上述节余募集资金永久补 充流动资金，用于公司日常经营及业务发展。 ●履行的审议程序：上述事项已经公司第九届董事会审计委员会第二次会议、 第九届董事会独立董事专门会议 2025 年第一次会议及第九届董事会第二次临时会 议审议通过，无需提交公司股东会审议，无需召开债券持有人会议。 一、募集资金及募投项目基本情况 （一）募集资金基本情况 经中国证券监督管理委员会证监许可[2020 ...

| 证券代码：600521 | 证券简称：华海药业 | 公告编号：临 | 2025-084 号 | | --- | --- | --- | --- | | 债券代码：110076 | 债券简称：华海转债 | | | 浙江华海药业股份有限公司 关于部分募集资金投资项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 浙江华海药业股份有限公司（以下简称"公司"）于 2025 年 7 月 24 日召 开第九届董事会第二次临时会议，审议通过了《关于部分募集资金投资项目延期的 议案》，一致同意将"制剂数字化智能制造建设项目"达到预定可使用状态的日期 延期至 2026 年 12 月。 本次募集资金投资项目延期仅涉及项目进度的调整，不存在改变或变相改 变募集资金用途的情况，不存在违规使用募集资金的情形，不会对公司的正常经营 产生重大不利影响，也不存在损害股东利益特别是中小股东利益的情形。 保荐机构已就本次部分募集资金投资项目延期事项发表了明确同意的意见。 该事项无需提交股东会审议。 一、募集资金基本情况 经中 ...

证券简称：华海药业 证券代码：600521 公告编号：临 2025-083 号 债券简称：华海转债 债券代码：110076 浙江华海药业股份有限公司 第九届董事会第二次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 具体内容详见公司于 2025 年 7 月 25 日刊登在中国证券报、上海证券报、证 券时报、证券日报及上海证券交易所网站（www.sse.com.cn）上的《浙江华海药 业股份有限公司关于部分募集资金投资项目延期的公告》。 2、审议通过了《关于募投项目结项并将节余募集资金永久补充流动资金的 议案》 表决情况：同意 9 票；反对 0 票；弃权 0 票。 会议决议：董事会同意募投项目"浙江华海生物科技有限公司 ADC 产业化 技改项目"结项并将节余募集资金永久补充流动资金。 1 / 2 该议案已经公司第九届董事会审计委员会第二次会议、第九届董事会独立董 事专门会议 2025 年第一次会议审议通过，且已经公司本次董事会审议通过。 浙江华海药业股份有限公司（以下称"公司"）第九届董事会第二次临时会 ...

浙江华海药业股份有限公司 独立董事专门会议 浙江华海药业股份有限公司 第九届董事会独立董事专门会议 2025 年第一次会议决议 浙江华海药业股份有限公司（以下简称"公司"）第九届董事会独立董事专门 会议 2025 年第一次会议于二零二五年七月十八日下午十五点在公司会议室以通 讯方式召开。会议应到会独立董事三人，实际到会独立董事三名，会议由公司独 立董事邓川先生主持，会议程序符合《中华人民共和国公司法》《上市公司独立董 事管理办法》及《公司章程》《公司独立董事工作制度》等相关规定，会议合法有 效。会议审议并通过了如下决议： 会议决议：公司募集资金投资项目"制剂数字化智能制造建设项目"延期事 项是根据项目实施的客观实际和经营需要作出的审慎决定，仅涉及项目进度的调 整，不涉及募投项目的投资内容、投资用途、投资总额、实施主体的变更，不存 在变相改变募集资金投向和损害公司股东利益的情形。因此，公司独立董事专门 会议同意本次部分募集资金投资项目延期事项。 二、审议通过了《关于募投项目结项并将节余募集资金永久补充流动资金的 议案》 表决情况：同意：3 票；反对：0 票；弃权：0 票。 会议决议：公司募投项目"浙江华海生物科 ...

Core Insights - Despite holding promising drug candidates like HB0034 and HB0025, Huahai Pharmaceutical's subsidiary Huatai has struggled to gain market traction, with its stock price dropping over 12% from a month ago [1][3] - Huatai's research pipeline includes leading candidates in the IL-36 and PD-1/VEGF dual antibody fields, yet it has failed to convert this potential into actual partnerships or product launches [2][3] - The company's innovative drug segment has become a financial burden, with significant losses projected for 2024 and a negative net asset position, raising concerns about its long-term viability [3][4] Group 1 - Huatai's HB0034 is the leading global candidate in the IL-36 space, with indications expanding from GPP to lupus and ulcerative colitis [2] - The PD-1/VEGF dual antibody HB0025 is targeting endometrial cancer and is nearing Phase III clinical trials [2] - Despite these advancements, Huatai has not secured any business development (BD) deals or product launches in over a decade [3] Group 2 - Huahai's core business remains strong, with over 30% market share in certain APIs and an 80% gross margin in its formulation business [3] - The innovative drug division's lack of product launches has led to a projected net loss of 330 million yuan in 2024, significantly impacting the parent company's profitability [3] - A performance guarantee agreement signed with investors requires Huahai to buy back shares if no products are launched within three years or if two products are not launched within five years [3][4] Group 3 - The current situation highlights a broader challenge within the Chinese biotech sector, where traditional revenue streams are dwindling while innovative pipelines struggle to realize value [4] - The company faces a critical decision on whether to wait for product approvals, accelerate business development efforts, or pivot its strategic focus [4]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 文/新浪财经上海站 陈秀颖 2025年上半年，中国创新药行业在政策红利与国际化突破的双重助力下迎来高光时刻，Wind数据显 示，A股创新药板块80家企业中，16家已发布中报预告。头部企业凭借技术壁垒与商业化能力实现爆发 式增长。 | 证券简称 | 预告净利润同比增长 | | 预告净利润同比增 董事长 | 总经理 | | --- | --- | --- | --- | --- | | | 上限 | 长下限 | | [交易日期] 最新 [交易日期] 最新 | | | [报告期] 今年中报 | [报告期] 今年中报 | | | | | [单位] %↓ | [单位] % | | | | 双鹭药业 | 356.24 | | 237.95 徐明波 | 徐明波 | | 全诺生物 | 332.10 | | 253.54 文永均 | 文永均 | | 步长制药 | 205.94 | | 110.88 赵涛 | #x15 | | 通化东宝 | 194.30 | | 194.30 李佳鸿 | 冷春生 | | 微芯生物 | 173.00 | | 173.00 X ...

Group 1 - The Alzheimer's concept sector increased by 2.28%, ranking fifth among concept sectors, with 27 stocks rising, including Wanbangde, Lisheng Pharmaceutical, and Zhejiang Zhenyuan reaching the daily limit [1] - Notable gainers in the sector included Jihua Group, Xinhua Pharmaceutical, and Boji Pharmaceutical, which rose by 5.85%, 4.98%, and 4.93% respectively [1] - The sector experienced a net inflow of 498 million yuan from main funds, with 21 stocks receiving net inflows, and six stocks seeing inflows exceeding 50 million yuan [2] Group 2 - The top stock in terms of net inflow was Huahai Pharmaceutical, with a net inflow of 87.51 million yuan, followed by Boji Pharmaceutical, Jihua Group, and Haizheng Pharmaceutical with inflows of 55.18 million yuan, 54.13 million yuan, and 53.91 million yuan respectively [2][3] - Zhejiang Zhenyuan and Boji Pharmaceutical had the highest net inflow ratios at 29.25% and 16.16% respectively [3] - The overall performance of the Alzheimer's concept sector was supported by significant trading volumes, with stocks like Lisheng Pharmaceutical and Wanbangde showing substantial price increases of 10% [4]

Policy Developments - The National Healthcare Security Administration reported that the basic medical insurance coverage rate in China remains stable at over 95%, with 1.32662 billion people insured by the end of 2024 [2] - The total income of the national basic medical insurance fund for 2024 is projected to be CNY 34,913.37 billion, while total expenditures are expected to be CNY 29,764.03 billion, resulting in a current balance of CNY 4,639.17 billion [2] - Since the establishment of the National Healthcare Security Administration in 2018, 835 new drugs have been added to the medical insurance drug list, with over 5,400 million CNY in sales from newly negotiated drugs between 2018 and 2024 [2] Drug and Device Approvals - Bayer's non-hormonal drug elinzanetant has been approved by the UK Medicines and Healthcare products Regulatory Agency for treating moderate to severe vasomotor symptoms related to menopause [5] - Innovent Biologics' new BCL2 inhibitor mesutoclax has received FDA approval to commence clinical trials for treating myeloid malignancies, including acute myeloid leukemia and myelodysplastic syndromes [6] - Tianyu Co., Ltd.'s subsidiary has passed the review for ezetimibe raw materials by the National Medical Products Administration, pending GMP compliance inspection results for market launch [7] Capital Market Activities - Innostellar Biotherapeutics has signed a ten-year exclusive promotion agreement with Golden Age Health for the commercialization of its gene therapy candidate LX101 in mainland China [9] Earnings Disclosures - Da'an Gene anticipates a net loss of CNY 140 million to 200 million for the first half of 2025 [11] - Huahai Pharmaceutical expects a net profit decline of 40% to 50% year-on-year, projecting a profit range of CNY 374 million to 449 million [12] - KingMed Diagnostics forecasts a net loss of CNY 95 million to 65 million for the first half of 2025, representing a significant year-on-year decline [13] - Xinmai Medical projects a net profit of CNY 304 million to 361 million for the first half of 2025, a decrease of 10.52% to 24.78% compared to the previous year [14] - Wantai Biological Pharmacy anticipates a net loss of CNY 130 million to 160 million for the first half of 2025 due to market pressures and policy adjustments [15] Industry Events - *ST Suwu has received a notice of administrative penalty from the China Securities Regulatory Commission for falsifying financial reports, which may lead to forced delisting [17] - This incident serves as a warning for the pharmaceutical industry to focus on genuine innovation and establish effective internal controls to mitigate risks associated with management [17] Shareholder Movements - Qihe Venture, a shareholder holding over 5% of Xuantai Pharmaceutical, plans to reduce its stake by up to 7 million shares, representing no more than 1.5441% of the company's total shares [19]